Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: Delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity

Bone Marrow Transplantation

Volumn 34, Issue 4, 2004, Pages 309-316

  Massenkeil, Gero ^a   Roigas, J ^a   Nagy, M ^a   Wille, A ^a   Stroszczynski, C ^a   Mapara, M Y ^a   Loening, S ^a   Dorken B ^a   Arnold, R ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Graft versus host disease (GvHD); Mixed chimerism (MC); Nonmyeloablative stem cell transplantation (NST); Renal cell carcinoma (RCC)

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GANCICLOVIR; GLUCOCORTICOID; HLA ANTIGEN; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BRAIN ISCHEMIA; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DATA ANALYSIS; DEATH; DISEASE COURSE; DISEASE SEVERITY; DONOR; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL INFECTION; GOUT; GRAFT VERSUS HOST REACTION; HEART ATRIUM FIBRILLATION; HLA MATCHING; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; KIDNEY CARCINOMA; KIDNEY FAILURE; LEUKOENCEPHALOPATHY; LYMPHOCYTE TRANSFUSION; MALE; MEDICAL LITERATURE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NEPHRECTOMY; PANCYTOPENIA; PATIENT SELECTION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SEIZURE; SEPSIS; STEM CELL TRANSPLANTATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION CHIMERA; TREATMENT OUTCOME;

EID: 4444372989     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704587     Document Type: Article

References (32)

1. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000; 27: 177-186.
2. Fairlamb DJ. Spontaneous regression of metastases of renal cancer: a report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature. Cancer 1981; 47: 2102-2106.
3. Figlin RA, Thompson JA, Bukowski RM et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999; 17: 2521-2529.
4. Chang AE, Li Q, Jiang G et al. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol 2003; 21: 884-890.
5. Atzpodien J, Kirchner H, Illiger HJ et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001; 85: 1130-1136.
6. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
7. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
8. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
9. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
10. Slavin S, Nagler A, Naparstek E et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematological diseases. Blood 1998; 91: 756-763.
11. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
12. Massenkeil G, Nagy M, Lawang M et al. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukemias if complete donor chimerism can be achieved. Bone Marrow Transplant 2003; 31: 339-345.
13. Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234-3241.
14. Bregni M, Dodero A, Peccatori J et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234-4236.
15. Pedrazzoli P, Da Prada GA, Giorgiani G et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 2002; 94: 2409-2415.
16. Rini BI, Zimmerman T, Stadler WM et al. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 2002; 20: 2017-2024.
17. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
18. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man: a clinicopathological study of 20 long-term Seattle patients. Am J Med 1980; 69: 204-217.
19. Nagy M, Massenkeil G, Anders P et al. Short tandem repeat analysis to monitor chimerism after allogeneic stem cell transplantation. In: Sensabaugh GF, Lincoln PJ, Olaisen B (eds). Progress in Forensic Genetics, 8: Proceedings of the 18th International ISFH Congress. San Francisco, CA, 2000; pp 561-563.
20. Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 1976; 3: 2303-2308.
21. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
22. Hinchey J, Chaves C, Appignani B et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334: 494-500.
23. Hentschke P, Barkholt L, Uzunel M et al. Low intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003; 31: 253-261.
24. Ueno NT, Cheng YC, Rondon G et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem-cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829-3836.
25. Blaise D, Bay JO, Faucher C et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004; 103: 435-441.
26. Shlomchik WD, Couzens MS, Tang CB et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415.
27. Mapara MY, Kim YM, Wang SP et al. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 2002; 100: 1903-1909.
28. Orsini E, Alyea EP, Chillemi A et al. Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. Biol Blood Marrow Transplant 2000; 6: 375-386.
29. Mickisch GHJ, Garin A, van Pappel H et al. Radical nephrectomy plus interferon-alpha-based immunotherapy compared with interferon-alpha alone in metastatic renal-cell-carcinoma: a randomised trial. Lancet 2001; 358: 966-970.
30. Storb RF, Lucarelli G, McSweeney PA, Childs RW. Hematopoietic cell transplantation for benign hematological disorders and solid tumors. Hematology (Am Soc Hematol Educ Program) 2003, 372-397.
31. Gijtenbeek JMM, van den Bent MJ, Vecht CH J. Cyclosporine neurotoxicity: a review. J Neurol 1999; 246: 339-346.
32. Sullivan KM, Agura E, Anasetti C et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.